Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma: Rare subset case report

Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at...

Full description

Saved in:

Bibliographic Details
Published in:	Urology case reports Vol. 55; p. 102798
Main Authors:	AlAkrash, Hamad S., Ghabbani, Hisham M., AlSaleh, Faisal A., Nassar, Rashad M., AlHumaidan, Almaha A., AlHasan, Abdullateef M., AlMosa, Abdullah M., AlBluwi, Abdulaziz A., Eltholoth, Hossam S., Ali, Nagoud M., AlZahrani, Ahmed Y.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-07-2024 Elsevier
Subjects:	Oncology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is a rare subtype of renal cell carcinoma characterized by genetic rearrangements involving the ALK gene. Managing ALK-RCC is challenging due to its rarity and limited treatment options. Targeted therapies directed at the ALK gene have shown promise. ALK-RCC is a rare subtype of renal cell carcinoma with unique clinical and pathological features. ALK inhibitors may hold promise as a targeted therapy for ALK-RCC. Further research is needed to understand the behavior of ALK-RCC and develop effective treatment strategies.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	2214-4420 2214-4420
DOI:	10.1016/j.eucr.2024.102798